SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Market Closed - Hong Kong S.E. Other stock markets 04:08:27 2024-07-12 am EDT			5-day change	1st Jan Change
13.58 ^HKD	+1.19%		-0.59%	-20.12%

11:32am	Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer	MT
Jul. 08	Shanghai Fosun Pharmaceutical (Group) Cancer Treatment Gets NMPA's Nod for Clinical Trials	MT

Other languages

Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer	05:32am
Shanghai Fosun Pharmaceutical (Group) Cancer Treatment Gets NMPA's Nod for Clinical Trials	Jul. 08
Shanghai Fosun Pharmaceutical Unit Gets Marketing Approval for Epilepsy Drug in China	Jul. 08
Shanghai Fosun Pharmaceutical Co., Ltd. Announces Board and Board Committee Changes	Jul. 01
Shanghai Fosun Pharmaceutical Gets Registration Application Approval for Chest Pain Drug	Jun. 28
Shanghai Fosun Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024	Jun. 26
Fosun Pharma Signs HK$13.4 Billion Merger Offer for Henlius Biotech; Henlius Shares Soar 19%	Jun. 25
Fosun Pharma Trims Stake in Gland Pharma to 51.83%	Jun. 20
Shanghai Fosun Pharmaceutical Co., Ltd. Announces Executive and Committee Changes	Jun. 19
Chinese Regulator Accepts Fosun Pharma Unit's Drug Registration Application for Luvometinib Tablets; Shares Up 3%	Jun. 07
Shanghai Fosun Pharmaceutical Buys Remaining 49% Stake in Nursing Home; Shares Rise 7%	Jun. 03
Shanghai Fosun Pharmaceutical (Group)'s Investigational New Drug Application Accepted by NMPA	May. 27
Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	May. 15
China Approves Clinical Trials For Breast Cancer Drugs	May. 15
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets	May. 09
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug	May. 09
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets	May. 07
Fosun Pharma's Q1 Profit Slumps 38%	Apr. 30
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	Apr. 24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Other languages

Filters